The PD-1 inhibitor nivolumab was efficacious in ~20% of HCC patients of all etiologies with significantly improved survival benefits compared to TKIs, and nivolumab and pembrolizumab have been approved for HCC treatment as a second line therapy following sorafenib [190]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.